Guest on France Inter on Sunday October 13, 2024, the first secretary of the Socialist Party attacked Sanofi’s sale of Doliprane to an American fund, denouncing a conflict of interest and a problem of health sovereignty.
The Sanofi laboratory announced on Friday October 18 the sale of its subsidiary Opella to the American investment fund CD&R. An announcement which is far from having delighted the deputy Olivier Faure, first secretary of the Socialist Party, who did not hesitate to express his concerns on France Inter: “We learned this week that Sanofi was going to sell its subsidiary Opella which currently produces Doliprane. It’s a scandal”he denounced.
“We thought we had learned some lessons from the Covid period. The Head of State explained that there was a problem of health sovereignty and that we now had to ensure that the medicines which are essential to our health were preserved on national soil”estimates Olivier Faure, who recalls that in the event of a shortage of medicines, “you know very well that the American government can request that priority be given” to citizens of the United States.
A French investment fund had positioned itself
A problem of health sovereignty which is coupled, for the MP, with a “major conflict of interest”, with a general director of Sanofi who “was bought for 200 million euros and who suddenly accepted this sale and an administrator who is also an administrator of this American fund”. He also castigates Patrick Kron, former general director of Alstom, “who had already been at the origin of the sale of Alstom to General Electric and who also participated in this choice”.
Olivier Faure also attacks the government and President Emmanuel Macron, who “takes care of ensuring that Emily in Paris stays in France. I would prefer that he takes care of ensuring that Doliprane remains French”he blurted out on France Inter. Because two investment funds had in fact positioned themselves for the takeover of Opella, including the French fund PAI Partners, which “had all the guarantees and produced an offer equivalent to that of the American fund”.
Olivier Faure, however, thinks that there is still time to prevent the sale politically, “not by nationalizing, but there is a law which allows, on health issues, to block a sale. It has not yet been contractualized and there is still a possibility that things will happen”, reminding Sanofi in passing that the laboratory received 1.5 billion euros over ten years in research tax credit (CIR) and that a factory opened in the Lyon metropolitan area was partly financed by the State amounting to 400 million euros.
published on October 13 at 5:54 p.m., Auguste Breton, 6Medias
Share
Related News :